Peripheral neuropathic pain is a chronic condition resulting from damage to peripheral nerves, often associated with diabetes, infections, or traumatic injuries. It accounts for a significant portion of global pain disorders, with around 50% of diabetics suffering from diabetic peripheral neuropathy. According to the peripheral neuropathic pain pipeline analysis by Expert Market Research, the pipeline is witnessing a surge in targeted therapeutics and novel drug development. Increasing R&D investments, advancements in pain management therapies, and a growing focus on non-opioid alternatives are expected to drive significant pipeline growth in the coming years.
Major companies involved in the peripheral neuropathic pain pipeline analysis include GlaxoSmithKline, Vertex Pharmaceuticals Incorporated, and others.
Leading drugs currently in the pipeline include RTA 901, GSK3858279, and others.
Advancements in non-opioid therapies, growing research on sodium channel blockers, and increased clinical trial activity for diabetic neuropathy and postherpetic neuralgia are driving significant pipeline growth.
The Peripheral Neuropathic Pain Pipeline Analysis Report by Expert Market Research gives comprehensive insights into peripheral neuropathic pain therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for peripheral neuropathic pain. The peripheral neuropathic pain report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The peripheral neuropathic pain pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with peripheral neuropathic pain treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to peripheral neuropathic pain.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Peripheral neuropathic pain is a chronic condition caused by damage or dysfunction in the peripheral nervous system. It often results from diabetes, infections, trauma, or toxins and leads to burning, tingling, or shooting pain. This occurs when damaged nerves send faulty pain signals to the brain, even without an actual injury or stimulus.
Peripheral neuropathic pain is treated using anticonvulsants, antidepressants, topical agents, and non-opioid analgesics to reduce nerve pain and improve quality of life. In January 2025, Vertex Pharmaceuticals advanced suzetrigine (Journavx) in its pipeline for peripheral neuropathic pain, including painful diabetic peripheral neuropathy, with ongoing Phase 3 trials evaluating its efficacy and safety.
An epidemiological study published in 2024 reported a 14.6% overall prevalence of peripheral neuropathic pain (PN). Prevalence increased with age, peaking at 18.9% among individuals aged 61-65 years. Female subjects showed a higher rate (15.9%) compared to males (13.0%). Obesity was also linked to elevated prevalence (16.0%). The mean age of PN patients was 54.3 years, and the mean body mass index (BMI) was 27.5 kg/m².
This section of the report covers the analysis of peripheral neuropathic pain drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total peripheral neuropathic pain clinical trials, with 41.94%, showing strong clinical focus and innovation. The other phases include phase III at 21.77%, phase IV at 16.94%, phase I at 14.52%, and early phase I at 4.84%. This robust pipeline, especially in later stages, indicates significant progress that could enhance treatment options in the peripheral neuropathic pain management.
The drug molecule categories covered under the peripheral neuropathic pain pipeline analysis include small molecules, biologics, gene therapies, peptides, RNA-based therapies, and others. The peripheral neuropathic pain report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for peripheral neuropathic pain.
Fatty acid binding protein (FABP) inhibitors are emerging as a novel drug class in the peripheral neuropathic pain pipeline. For instance, ART26.12, a selective fatty acid binding protein (FABP) inhibitor developed by Artelo Biosciences, is progressing through Phase 1 clinical trials. This non-opioid candidate targets chemotherapy-induced peripheral neuropathy by modulating the endocannabinoid system, offering a potential alternative to conventional pain therapies.
The EMR report for the peripheral neuropathic pain pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed peripheral neuropathic pain therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in peripheral neuropathic pain clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for peripheral neuropathic pain. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of peripheral neuropathic pain drug candidates.
VX-993, sponsored by Vertex Pharmaceuticals Incorporated, is being evaluated in a Phase II trial for its efficacy, safety, and tolerability in treating pain associated with diabetic peripheral neuropathy. The study aims to examine dose response and compare VX-993 with pregabalin and placebo. VX-993 is a selective NaV1.8 inhibitor targeting peripheral pain signaling without opioid-related risks.
GSK3858279 is currently being evaluated in a Phase 2 clinical trial for diabetic peripheral neuropathic pain. Developed by GlaxoSmithKline, this monoclonal antibody targets the CCL17 protein, aiming to interrupt pain signaling pathways. The study is assessing its efficacy in pain reduction, while also examining safety, tolerability, pharmacokinetics, and target engagement in adults with chronic DPNP.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Peripheral Neuropathic Pain Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for peripheral neuropathic pain. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into peripheral neuropathic pain collaborations, regulatory environments, and potential growth opportunities.
Global Peripheral Neuropathy Treatment Market Report and Forecast
Diabetic Peripheral Neuropathy Drug Pipeline Analysis Report
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share